| Name | Title | Contact Details |
|---|
Polyzen develops and manufactures disposable medical products and devices for medical industry original equipment manufacturers.
Find a barre3® studio near you or subscribe to barre3 Online and start an online workout today.
MetCap Living is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2004, BioRx is a national provider of specialty pharmacy, infusion management and industry consulting services. As a private, independently-owned company, BioRx is committed to a flexible service model that meets the needs of its customers, including consumers, healthcare providers, health plans and pharmaceutical manufacturers. The company’s streamlined management structure allows it to respond more quickly to changes in the marketplace and provide a higher level of service that is customized for each consumer. Moreover, BioRx helps to provide a more cost-effective level of healthcare – in particular by moving patients from costly facility-based infusion sites to their homes, thereby allowing us to closely monitor the administration and outcomes of complex infusion therapies. BioRx consumer services include home delivery of specialty intravenous and injectable pharmaceuticals, medical supplies, nursing support, reimbursement coordination, consumer advocacy, and highly customized care plans. The company also provides professional consulting services to business partners within the insurance and pharmaceutical manufacturing industries.
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.